Valuation: Chugai Pharmaceutical Co., Ltd.

Market Cap 11,405B 71.57B 62.22B 57.91B 53.17B 100B 6,832B 102B 683B 268B 3,401B 269B 263B P/E 2026 *
22.5x
P/E 2027 * 19.3x
Enterprise Value 10,493B 65.84B 57.24B 53.28B 48.91B 92.37B 6,285B 93.8B 628B 246B 3,129B 247B 242B EV / Sales 2026 *
7.55x
EV / Sales 2027 * 6.66x
Free-Float
38.12%
Yield 2026 *
1.98%
Yield 2027 * 2.26%
1 day-1.97%
1 week-6.53%
1 month-7.99%
3 months-14.59%
6 months-21.24%
Current year-15.90%
1 week 6,795
Extreme 6795
7,149
1 month 6,795
Extreme 6795
7,939
Current year 6,795
Extreme 6795
10,700
1 year 5,942
Extreme 5942
10,700
3 years 4,076
Extreme 4076
10,700
5 years 3,191
Extreme 3191
10,700
10 years 1,003.33
Extreme 1003.3333
10,700
Manager TitleAgeSince
Chief Executive Officer 63 28/02/2021
Director of Finance/CFO 59 27/03/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 63 29/02/2020
Director/Board Member 59 27/03/2024
Director/Board Member 51 28/02/2025
Change 5-day change 1-year change 3-year change Capi.($)
-1.97%-6.53%-5.82%+63.84% 71.57B
-0.53%-3.95%+55.23%+152.74% 1,024B
+0.21%-2.68%+55.61%+53.02% 618B
-2.51%-3.25%+32.76%+67.76% 443B
+0.06%-0.42%+37.53%+30.67% 349B
-0.14%-0.24%+34.41%+39.01% 297B
-0.69%-0.30%+11.55%+12.93% 264B
-7.37%-4.40%-2.54%-43.87% 209B
-0.64%+2.43%+30.52%+64.49% 208B
-0.82%+0.70%+15.96%+71.01% 162B
Average -1.44%-1.73%+26.52%+51.16% 364.53B
Weighted average by Cap. -1.01%-2.02%+38.35%+72.78%

Financials

2026 *2027 *
Net sales 1,390B 8.72B 7.58B 7.06B 6.48B 12.24B 833B 12.43B 83.2B 32.65B 415B 32.76B 32.04B 1,538B 9.65B 8.39B 7.81B 7.17B 13.54B 921B 13.75B 92.04B 36.12B 459B 36.24B 35.45B
Net income 508B 3.19B 2.77B 2.58B 2.37B 4.47B 304B 4.54B 30.4B 11.93B 151B 11.97B 11.71B 592B 3.71B 3.23B 3B 2.76B 5.21B 354B 5.29B 35.42B 13.9B 176B 13.95B 13.64B
Net Debt -913B -5.73B -4.98B -4.63B -4.25B -8.03B -547B -8.16B -54.62B -21.44B -272B -21.51B -21.04B -1,162B -7.29B -6.34B -5.9B -5.42B -10.23B -696B -10.39B -69.58B -27.31B -347B -27.4B -26.79B
Logo Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Employees
5,104
Date Price Change Volume
31/07/26 JP¥6,932.00 -1.97% 2,876,800
30/07/26 JP¥7,071.00 +0.03% 2,701,800
29/07/26 JP¥7,069.00 +1.00% 2,859,900
28/07/26 JP¥6,999.00 +2.21% 4,135,500
27/07/26 JP¥6,848.00 -7.66% 6,311,000
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
6,932.00JPY
Average target price
9,686.67JPY
Spread / Average Target
+39.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4519 Stock